SKYE vs DBVT vs HALO vs ABBV vs MRK

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus 1. 2% for Merck & Co. , Inc. (MRK). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus AbbVie Inc. at 85. 5x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 35x versus Merck & Co. , Inc. 's 1. 03x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -96. 0% for Skye Bioscience, Inc. (SKYE). Over 10 years, the gap is even starker: HALO returned +570. 7% versus SKYE's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Skye Bioscience, Inc. 's 2. 36β — meaning SKYE is approximately 597% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Skye Bioscience, Inc. (SKYE) carries a lower debt/equity ratio of 1% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus 1. 2% for Merck & Co. , Inc. (MRK). On earnings-per-share growth, the picture is similar: Merck & Co. , Inc. grew EPS 8. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — HALO leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 35x versus Merck & Co. , Inc. 's 1. 03x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 1x forward P/E versus 21. 9x for Merck & Co. , Inc. — 13. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, ABBV (3.

2% yield), MRK (2. 9% yield) pay a dividend. SKYE, DBVT, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Skye Bioscience, Inc. (SKYE) carries a higher beta of 2. 36 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, SKYE: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SKYE is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; HALO is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock; MRK is a large-cap deep-value stock. ABBV, MRK pay a dividend while SKYE, DBVT, HALO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.